1nhz › Citations

The three-dimensional structures of antagonistic and agonistic forms of the glucocorticoid receptor ligand-binding domain: RU-486 induces a transconformation that leads to active antagonism.

Kauppi B, Jakob C, Färnegårdh M, Yang J, Ahola H, Alarcon M, Calles K, Engström O, Harlan J, Muchmore S, Ramqvist AK, Thorell S, Ohman L, Greer J, Gustafsson JA, Carlstedt-Duke J, Carlquist M
J Biol Chem 278 22748-54 (2003)
Cited: 192 times
EuropePMC logo PMID: 12686538

Abstract

Here we describe the three-dimensional crystal structures of human glucocorticoid receptor ligand-binding domain (GR-LBD) in complex with the antagonist RU-486 at 2.3 A resolution and with the agonist dexamethasone ligand together with a coactivator peptide at 2.8 A. The RU-486 structure was solved in several different crystal forms, two with helix 12 intact (GR1 and GR3) and one with a protease-digested C terminus (GR2). In GR1, part of helix 12 is in a position that covers the co-activator pocket, whereas in the GR3, domain swapping is seen between the crystallographically identical subunits in the GR dimer. An arm consisting of the end of helix 11 and beyond stretches out from one molecule, and helix 12 binds to the other LBD, partly blocking the coactivator pocket of that molecule. This type of GR-LBD dimer has not been described before but might be an artifact from crystallization. Furthermore, the subunits of the GR3 dimers are covalently connected via a disulfide bond between the Cys-736 residues in the two molecules. All three RU-486 GR-LBD structures show that GR has a very flexible region between the end of helix 11 and the end of helix 12.

Reviews - 1nhz mentioned but not cited (1)

  1. The Biologist's Guide to the Glucocorticoid Receptor's Structure. Deploey N, Van Moortel L, Rogatsky I, Peelman F, De Bosscher K. Cells 12 1636 (2023)

Articles - 1nhz mentioned but not cited (30)

  1. Drug discovery using chemical systems biology: identification of the protein-ligand binding network to explain the side effects of CETP inhibitors. Xie L, Li J, Xie L, Bourne PE. PLoS Comput Biol 5 e1000387 (2009)
  2. Human glucocorticoid receptor beta binds RU-486 and is transcriptionally active. Lewis-Tuffin LJ, Jewell CM, Bienstock RJ, Collins JB, Cidlowski JA. Mol Cell Biol 27 2266-2282 (2007)
  3. A system-level investigation into the mechanisms of Chinese Traditional Medicine: Compound Danshen Formula for cardiovascular disease treatment. Li X, Xu X, Wang J, Yu H, Wang X, Yang H, Xu H, Tang S, Li Y, Yang L, Huang L, Wang Y, Yang S. PLoS One 7 e43918 (2012)
  4. Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs. Bisson WH, Cheltsov AV, Bruey-Sedano N, Lin B, Chen J, Goldberger N, May LT, Christopoulos A, Dalton JT, Sexton PM, Zhang XK, Abagyan R. Proc Natl Acad Sci U S A 104 11927-11932 (2007)
  5. The X-ray structure of RU486 bound to the progesterone receptor in a destabilized agonistic conformation. Raaijmakers HC, Versteegh JE, Uitdehaag JC. J Biol Chem 284 19572-19579 (2009)
  6. Synthesis, spectral characterization, and in vitro cellular activities of metapristone, a potential cancer metastatic chemopreventive agent derived from mifepristone (RU486). Wang J, Chen J, Wan L, Shao J, Lu Y, Zhu Y, Ou M, Yu S, Chen H, Jia L. AAPS J 16 289-298 (2014)
  7. Glucocorticoid protection of oligodendrocytes against excitotoxin involving hypoxia-inducible factor-1alpha in a cell-type-specific manner. Sun YY, Wang CY, Hsu MF, Juan SH, Chang CY, Chou CM, Yang LY, Hung KS, Xu J, Lee YH, Hsu CY. J Neurosci 30 9621-9630 (2010)
  8. Astragaloside IV inhibits microglia activation via glucocorticoid receptor mediated signaling pathway. Liu HS, Shi HL, Huang F, Peterson KE, Wu H, Lan YY, Zhang BB, He YX, Woods T, Du M, Wu XJ, Wang ZT. Sci Rep 6 19137 (2016)
  9. A Receptor Model With Binding Affinity, Activation Efficacy, and Signal Amplification Parameters for Complex Fractional Response Versus Occupancy Data. Buchwald P. Front Pharmacol 10 605 (2019)
  10. Large-scale reverse docking profiles and their applications. Lee M, Kim D. BMC Bioinformatics 13 Suppl 17 S6 (2012)
  11. Design and synthesis of isothiocyanate-containing hybrid androgen receptor (AR) antagonist to downregulate AR and induce ferroptosis in GSH-Deficient prostate cancer cells. Qin Z, Ou S, Xu L, Sorensen K, Zhang Y, Hu DP, Yang Z, Hu WY, Chen F, Prins GS. Chem Biol Drug Des 97 1059-1078 (2021)
  12. Discovery of Novel GR Ligands toward Druggable GR Antagonist Conformations Identified by MD Simulations and Markov State Model Analysis. Hu X, Pang J, Zhang J, Shen C, Chai X, Wang E, Chen H, Wang X, Duan M, Fu W, Xu L, Kang Y, Li D, Xia H, Hou T. Adv Sci (Weinh) 9 e2102435 (2022)
  13. The anti-inflammatory and immunomodulatory potential of braylin: Pharmacological properties and mechanisms by in silico, in vitro and in vivo approaches. Espírito-Santo RF, Meira CS, Costa RDS, Souza Filho OP, Evangelista AF, Trossini GHG, Ferreira GM, Velozo EDS, Villarreal CF, Pereira Soares MB. PLoS One 12 e0179174 (2017)
  14. Dual targeting of cytokine storm and viral replication in COVID-19 by plant-derived steroidal pregnanes: An in silico perspective. Gyebi GA, Ogunyemi OM, Ibrahim IM, Afolabi SO, Adebayo JO. Comput Biol Med 134 104406 (2021)
  15. FRAGSITE: A Fragment-Based Approach for Virtual Ligand Screening. Zhou H, Cao H, Skolnick J. J Chem Inf Model 61 2074-2089 (2021)
  16. Fragment-based docking: development of the CHARMMing Web user interface as a platform for computer-aided drug design. Pevzner Y, Frugier E, Schalk V, Caflisch A, Woodcock HL. J Chem Inf Model 54 2612-2620 (2014)
  17. Using a Consensus Docking Approach to Predict Adverse Drug Reactions in Combination Drug Therapies for Gulf War Illness. Jaundoo R, Bohmann J, Gutierrez GE, Klimas N, Broderick G, Craddock TJA. Int J Mol Sci 19 E3355 (2018)
  18. Computational prediction and analysis of breast cancer targets for 6-methyl-1, 3, 8-trichlorodibenzofuran. Chitrala KN, Yeguvapalli S. PLoS One 9 e109185 (2014)
  19. Novel RU486 (mifepristone) analogues with increased activity against Venezuelan Equine Encephalitis Virus but reduced progesterone receptor antagonistic activity. DeBono A, Thomas DR, Lundberg L, Pinkham C, Cao Y, Graham JD, Clarke CL, Wagstaff KM, Shechter S, Kehn-Hall K, Jans DA. Sci Rep 9 2634 (2019)
  20. Synthesis and structure-activity relationship studies of novel dihydropyridones as androgen receptor modulators. Pepe A, Pamment M, Kim YS, Lee S, Lee MJ, Beebe K, Filikov A, Neckers L, Trepel JB, Malhotra SV. J Med Chem 56 8280-8297 (2013)
  21. The anticancer plant triterpenoid, avicin D, regulates glucocorticoid receptor signaling: implications for cellular metabolism. Haridas V, Xu ZX, Kitchen D, Jiang A, Michels P, Gutterman JU. PLoS One 6 e28037 (2011)
  22. Chemoproteomic profiling reveals cellular targets of nitro-fatty acids. Fang MY, Huang KH, Tu WJ, Chen YT, Pan PY, Hsiao WC, Ke YY, Tsou LK, Zhang MM. Redox Biol 46 102126 (2021)
  23. Mode of Action of Shan-Zhu-Yu (Cornus officinalis Sieb. et Zucc.) in the Treatment of Depression Based on Network Pharmacology. Liu P, Yang P, Zhang L. Evid Based Complement Alternat Med 2020 8838888 (2020)
  24. Relating the shape of protein binding sites to binding affinity profiles: is there an association? Simon Z, Vigh-Smeller M, Peragovics A, Csukly G, Zahoránszky-Kohalmi G, Rauscher AA, Jelinek B, Hári P, Bitter I, Málnási-Csizmadia A, Czobor P. BMC Struct Biol 10 32 (2010)
  25. Virtual screening of potentially endocrine-disrupting chemicals against nuclear receptors and its application to identify PPARγ-bound fatty acids. Jaladanki CK, He Y, Zhao LN, Maurer-Stroh S, Loo LH, Song H, Fan H. Arch Toxicol 95 355-374 (2021)
  26. A Novel Glucocorticoid and Androgen Receptor Modulator Reduces Viral Entry and Innate Immune Inflammatory Responses in the Syrian Hamster Model of SARS-CoV-2 Infection. Rocha SM, Fagre AC, Latham AS, Cummings JE, Aboellail TA, Reigan P, Aldaz DA, McDermott CP, Popichak KA, Kading RC, Schountz T, Theise ND, Slayden RA, Tjalkens RB. Front Immunol 13 811430 (2022)
  27. Chemical systems biology reveals mechanisms of glucocorticoid receptor signaling. Bruno NE, Nwachukwu JC, Srinivasan S, Nettles CC, Izard T, Jin Z, Nowak J, Cameron MD, Boregowda SV, Phinney DG, Elemento O, Liu X, Ortlund EA, Houtman R, Stavreva DA, Hager GL, Kamenecka TM, Kojetin DJ, Nettles KW. Nat Chem Biol 17 307-316 (2021)
  28. Selaginellin B induces apoptosis and autophagy in pancreatic cancer cells via the JAK2/STAT3 signaling pathway. Chu P, Wang S, Zhu X, Yang Y, Li H, Tesfaldet T, Shopit A, Yang Y, Ma X, Peng J, Tang Z, Sun Z. Am J Transl Res 12 7127-7143 (2020)
  29. Detecting Drug-Target Interactions with Feature Similarity Fusion and Molecular Graphs. Lin X, Xu S, Liu X, Zhang X, Hu J. Biology (Basel) 11 967 (2022)
  30. Towards a Treatment for Gulf War Illness: A Consensus Docking Approach. Jaundoo R, Bohmann J, Gutierrez GE, Klimas N, Broderick G, Craddock TJA. Mil Med 185 554-561 (2020)


Reviews citing this publication (44)

  1. Antiinflammatory action of glucocorticoids--new mechanisms for old drugs. Rhen T, Cidlowski JA. N Engl J Med 353 1711-1723 (2005)
  2. Androgen receptor: structure, role in prostate cancer and drug discovery. Tan MH, Li J, Xu HE, Melcher K, Yong EL. Acta Pharmacol Sin 36 3-23 (2015)
  3. Chemistry and structural biology of androgen receptor. Gao W, Bohl CE, Dalton JT. Chem Rev 105 3352-3370 (2005)
  4. Glucocorticoid receptor control of transcription: precision and plasticity via allostery. Weikum ER, Knuesel MT, Ortlund EA, Yamamoto KR. Nat Rev Mol Cell Biol 18 159-174 (2017)
  5. Structural overview of the nuclear receptor superfamily: insights into physiology and therapeutics. Huang P, Chandra V, Rastinejad F. Annu Rev Physiol 72 247-272 (2010)
  6. Update on glucocorticoid action and resistance. Ito K, Chung KF, Adcock IM. J Allergy Clin Immunol 117 522-543 (2006)
  7. The human glucocorticoid receptor: molecular basis of biologic function. Nicolaides NC, Galata Z, Kino T, Chrousos GP, Charmandari E. Steroids 75 1-12 (2010)
  8. A General Introduction to Glucocorticoid Biology. Timmermans S, Souffriau J, Libert C. Front Immunol 10 1545 (2019)
  9. Ligand control of coregulator recruitment to nuclear receptors. Nettles KW, Greene GL. Annu Rev Physiol 67 309-333 (2005)
  10. Human glucocorticoid receptor isoform beta: recent understanding of its potential implications in physiology and pathophysiology. Kino T, Su YA, Chrousos GP. Cell Mol Life Sci 66 3435-3448 (2009)
  11. Structure and function of steroid receptor AF1 transactivation domains: induction of active conformations. Lavery DN, McEwan IJ. Biochem J 391 449-464 (2005)
  12. The nuclear receptor superfamily and drug discovery. Moore JT, Collins JL, Pearce KH. ChemMedChem 1 504-523 (2006)
  13. Understanding nuclear receptor form and function using structural biology. Rastinejad F, Huang P, Chandra V, Khorasanizadeh S. J Mol Endocrinol 51 T1-T21 (2013)
  14. Androgen receptor antagonists for prostate cancer therapy. Helsen C, Van den Broeck T, Voet A, Prekovic S, Van Poppel H, Joniau S, Claessens F. Endocr Relat Cancer 21 T105-18 (2014)
  15. Drug insight: selective agonists and antagonists of the glucocorticoid receptor. McMaster A, Ray DW. Nat Clin Pract Endocrinol Metab 4 91-101 (2008)
  16. A structural perspective on nuclear receptors as targets of environmental compounds. Delfosse V, Maire AL, Balaguer P, Bourguet W. Acta Pharmacol Sin 36 88-101 (2015)
  17. Computational prediction of human drug metabolism. Ekins S, Andreyev S, Ryabov A, Kirillov E, Rakhmatulin EA, Bugrim A, Nikolskaya T. Expert Opin Drug Metab Toxicol 1 303-324 (2005)
  18. Allosteric controls of nuclear receptor function in the regulation of transcription. Billas I, Moras D. J Mol Biol 425 2317-2329 (2013)
  19. Modelling the glucocorticoid receptor and producing therapeutic agents with anti-inflammatory effects but reduced side-effects. McMaster A, Ray DW. Exp Physiol 92 299-309 (2007)
  20. Targeting alternative sites on the androgen receptor to treat castration-resistant prostate cancer. Lallous N, Dalal K, Cherkasov A, Rennie PS. Int J Mol Sci 14 12496-12519 (2013)
  21. Mineralocorticoid receptor binding, structure and function. Rogerson FM, Brennan FE, Fuller PJ. Mol Cell Endocrinol 217 203-212 (2004)
  22. Glucocorticoid receptor function in health and disease. Caratti G, Matthews L, Poolman T, Kershaw S, Baxter M, Ray D. Clin Endocrinol (Oxf) 83 441-448 (2015)
  23. Structural and functional relationships of the steroid hormone receptors' N-terminal transactivation domain. Kumar R, Litwack G. Steroids 74 877-883 (2009)
  24. The evolution of progesterone receptor ligands. Madauss KP, Stewart EL, Williams SP. Med Res Rev 27 374-400 (2007)
  25. Cortisol resistance in the New World revisited. Fuller PJ, Smith BJ, Rogerson FM. Trends Endocrinol Metab 15 296-299 (2004)
  26. Understanding how long-acting β2 -adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids in asthma - an update. Newton R, Giembycz MA. Br J Pharmacol 173 3405-3430 (2016)
  27. Androgen receptor as a therapeutic target. Gao W. Adv Drug Deliv Rev 62 1277-1284 (2010)
  28. Discovery of novel nuclear receptor modulating ligands: an integral role for peptide interaction profiling. Pearce KH, Iannone MA, Simmons CA, Gray JG. Drug Discov Today 9 741-751 (2004)
  29. GR Dimerization and the Impact of GR Dimerization on GR Protein Stability and Half-Life. Louw A. Front Immunol 10 1693 (2019)
  30. Structure of the glucocorticoid receptor, a flexible protein that can adapt to different ligands. Veleiro AS, Alvarez LD, Eduardo SL, Burton G. ChemMedChem 5 649-659 (2010)
  31. Modulation of HIV-1 virulence via the host glucocorticoid receptor: towards further understanding the molecular mechanisms of HIV-1 pathogenesis. Hapgood JP, Tomasicchio M. Arch Virol 155 1009-1019 (2010)
  32. Convergence of lipid homeostasis through liver X and thyroid hormone receptors. Berkenstam A, Färnegårdh M, Gustafsson JA. Mech Ageing Dev 125 707-717 (2004)
  33. Mechanisms of prostate cancer progression to androgen independence. McPhaul MJ. Best Pract Res Clin Endocrinol Metab 22 373-388 (2008)
  34. Ensemble allosteric model: energetic frustration within the intrinsically disordered glucocorticoid receptor. White JT, Li J, Grasso E, Wrabl JO, Hilser VJ. Philos Trans R Soc Lond B Biol Sci 373 20170175 (2018)
  35. Structures of androgen receptor bound with ligands: advancing understanding of biological functions and drug discovery. Sakkiah S, Ng HW, Tong W, Hong H. Expert Opin Ther Targets 20 1267-1282 (2016)
  36. Dimerization of the Glucocorticoid Receptor and Its Importance in (Patho)physiology: A Primer. Timmermans S, Vandewalle J, Libert C. Cells 11 683 (2022)
  37. New lead compounds in the search for pure antiglucocorticoids and the dissociation of antiglucocorticoid effects. Pecci A, Alvarez LD, Veleiro AS, Ceballos NR, Lantos CP, Burton G. J Steroid Biochem Mol Biol 113 155-162 (2009)
  38. Structural insights into glucocorticoid receptor function. Frank F, Ortlund EA, Liu X. Biochem Soc Trans 49 2333-2343 (2021)
  39. Splice variants in the proteome: a promising and challenging field to targeted drug discovery. Tavares R, Scherer NM, Ferreira CG, Costa FF, Passetti F. Drug Discov Today 20 353-360 (2015)
  40. Helix 3-helix 5 interactions in steroid hormone receptor function. Zhang J, Geller DS. J Steroid Biochem Mol Biol 109 279-285 (2008)
  41. Rational structure-based drug design and optimization in the ligand-binding domain of the glucocorticoid receptor-α. Onnis V, Kinsella GK, Carta G, Fayne D, Lloyd DG. Future Med Chem 1 345-359 (2009)
  42. Aldosterone and DNA: the 50th anniversary. Fuller PJ. Trends Endocrinol Metab 15 143-146 (2004)
  43. Drug design strategies for Cushing's syndrome. Usanov SA, Kliuchenovich AV, Strushkevich NV. Expert Opin Drug Discov 14 143-151 (2019)
  44. The aldosterone receptor--new insights? Fuller P. Expert Opin Investig Drugs 15 201-203 (2006)

Articles citing this publication (117)

  1. The glucocorticoid receptor dimer interface allosterically transmits sequence-specific DNA signals. Watson LC, Kuchenbecker KM, Schiller BJ, Gross JD, Pufall MA, Yamamoto KR. Nat Struct Mol Biol 20 876-883 (2013)
  2. Structural basis for accommodation of nonsteroidal ligands in the androgen receptor. Bohl CE, Miller DD, Chen J, Bell CE, Dalton JT. J Biol Chem 280 37747-37754 (2005)
  3. Ligand-selective transactivation and transrepression via the glucocorticoid receptor: role of cofactor interaction. Ronacher K, Hadley K, Avenant C, Stubsrud E, Simons SS, Louw A, Hapgood JP. Mol Cell Endocrinol 299 219-231 (2009)
  4. Signaling pathway of ginsenoside-Rg1 leading to nitric oxide production in endothelial cells. Leung KW, Cheng YK, Mak NK, Chan KK, Fan TP, Wong RN. FEBS Lett 580 3211-3216 (2006)
  5. Role of mitochondrial glucocorticoid receptor in glucocorticoid-induced apoptosis. Sionov RV, Cohen O, Kfir S, Zilberman Y, Yefenof E. J Exp Med 203 189-201 (2006)
  6. A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity. Dietz JD, Du S, Bolten CW, Payne MA, Xia C, Blinn JR, Funder JW, Hu X. Hypertension 51 742-748 (2008)
  7. Hydrogen/deuterium-exchange (H/D-Ex) of PPARgamma LBD in the presence of various modulators. Hamuro Y, Coales SJ, Morrow JA, Molnar KS, Tuske SJ, Southern MR, Griffin PR. Protein Sci 15 1883-1892 (2006)
  8. Doubling the size of the glucocorticoid receptor ligand binding pocket by deacylcortivazol. Suino-Powell K, Xu Y, Zhang C, Tao YG, Tolbert WD, Simons SS, Xu HE. Mol Cell Biol 28 1915-1923 (2008)
  9. Crystal structure of the T877A human androgen receptor ligand-binding domain complexed to cyproterone acetate provides insight for ligand-induced conformational changes and structure-based drug design. Bohl CE, Wu Z, Miller DD, Bell CE, Dalton JT. J Biol Chem 282 13648-13655 (2007)
  10. Crystal structure of a mutant mineralocorticoid receptor responsible for hypertension. Fagart J, Huyet J, Pinon GM, Rochel M, Mayer C, Rafestin-Oblin ME. Nat Struct Mol Biol 12 554-555 (2005)
  11. The glucocorticoid agonist activities of mifepristone (RU486) and progesterone are dependent on glucocorticoid receptor levels but not on EC50 values. Zhang S, Jonklaas J, Danielsen M. Steroids 72 600-608 (2007)
  12. Molecular switch in the glucocorticoid receptor: active and passive antagonist conformations. Schoch GA, D'Arcy B, Stihle M, Burger D, Bär D, Benz J, Thoma R, Ruf A. J Mol Biol 395 568-577 (2010)
  13. Bisphenol-A can bind to human glucocorticoid receptor as an agonist: an in silico study. Prasanth GK, Divya LM, Sadasivan C. J Appl Toxicol 30 769-774 (2010)
  14. Changes in plasma ACTH levels and corticotroph tumor size in patients with Cushing's disease during long-term treatment with the glucocorticoid receptor antagonist mifepristone. Fleseriu M, Findling JW, Koch CA, Schlaffer SM, Buchfelder M, Gross C. J Clin Endocrinol Metab 99 3718-3727 (2014)
  15. The glucocorticoid receptor represses cyclin D1 by targeting the Tcf-beta-catenin complex. Takayama S, Rogatsky I, Schwarcz LE, Darimont BD. J Biol Chem 281 17856-17863 (2006)
  16. Large-scale analysis of thermostable, mammalian proteins provides insights into the intrinsically disordered proteome. Galea CA, High AA, Obenauer JC, Mishra A, Park CG, Punta M, Schlessinger A, Ma J, Rost B, Slaughter CA, Kriwacki RW. J Proteome Res 8 211-226 (2009)
  17. Structures and mechanism for the design of highly potent glucocorticoids. He Y, Yi W, Suino-Powell K, Zhou XE, Tolbert WD, Tang X, Yang J, Yang H, Shi J, Hou L, Jiang H, Melcher K, Xu HE. Cell Res 24 713-726 (2014)
  18. Unliganded and hormone-bound glucocorticoid receptors interact with distinct hydrophobic sites in the Hsp90 C-terminal domain. Fang L, Ricketson D, Getubig L, Darimont B. Proc Natl Acad Sci U S A 103 18487-18492 (2006)
  19. A hydrophobic ratchet entrenches molecular complexes. Hochberg GKA, Liu Y, Marklund EG, Metzger BPH, Laganowsky A, Thornton JW. Nature 588 503-508 (2020)
  20. A conformational switch in the ligand-binding domain regulates the dependence of the glucocorticoid receptor on Hsp90. Ricketson D, Hostick U, Fang L, Yamamoto KR, Darimont BD. J Mol Biol 368 729-741 (2007)
  21. Molecular and pharmacological properties of a potent and selective novel nonsteroidal progesterone receptor agonist tanaproget. Zhang Z, Olland AM, Zhu Y, Cohen J, Berrodin T, Chippari S, Appavu C, Li S, Wilhem J, Chopra R, Fensome A, Zhang P, Wrobel J, Unwalla RJ, Lyttle CR, Winneker RC. J Biol Chem 280 28468-28475 (2005)
  22. The 11-ketosteroid 11-ketodexamethasone is a glucocorticoid receptor agonist. Rebuffat AG, Tam S, Nawrocki AR, Baker ME, Frey BM, Frey FJ, Odermatt A. Mol Cell Endocrinol 214 27-37 (2004)
  23. Atlas of tissue renin-angiotensin-aldosterone system in human: A transcriptomic meta-analysis. Nehme A, Cerutti C, Dhaouadi N, Gustin MP, Courand PY, Zibara K, Bricca G. Sci Rep 5 10035 (2015)
  24. Glucocorticoid receptor ligand binding domain is sufficient for the modulation of glucocorticoid induction properties by homologous receptors, coactivator transcription intermediary factor 2, and Ubc9. Cho S, Kagan BL, Blackford JA, Szapary D, Simons SS. Mol Endocrinol 19 290-311 (2005)
  25. Molecular dynamics simulations reveal multiple pathways of ligand dissociation from thyroid hormone receptors. Martínez L, Sonoda MT, Webb P, Baxter JD, Skaf MS, Polikarpov I. Biophys J 89 2011-2023 (2005)
  26. Trifluoromethyl group as a pharmacophore: effect of replacing a CF3 group on binding and agonist activity of a glucocorticoid receptor ligand. Betageri R, Zhang Y, Zindell RM, Kuzmich D, Kirrane TM, Bentzien J, Cardozo M, Capolino AJ, Fadra TN, Nelson RM, Paw Z, Shih DT, Shih CK, Zuvela-Jelaska L, Nabozny G, Thomson DS. Bioorg Med Chem Lett 15 4761-4769 (2005)
  27. Mechanisms for the evolution of a derived function in the ancestral glucocorticoid receptor. Carroll SM, Ortlund EA, Thornton JW. PLoS Genet 7 e1002117 (2011)
  28. Antcin A, a steroid-like compound from Antrodia camphorata, exerts anti-inflammatory effect via mimicking glucocorticoids. Chen YC, Liu YL, Li FY, Chang CI, Wang SY, Lee KY, Li SL, Chen YP, Jinn TR, Tzen JT. Acta Pharmacol Sin 32 904-911 (2011)
  29. Conformational changes of the glucocorticoid receptor ligand binding domain induced by ligand and cofactor binding, and the location of cofactor binding sites determined by hydrogen/deuterium exchange mass spectrometry. Frego L, Davidson W. Protein Sci 15 722-730 (2006)
  30. Insights on glucocorticoid receptor activity modulation through the binding of rigid steroids. Presman DM, Alvarez LD, Levi V, Eduardo S, Digman MA, Martí MA, Veleiro AS, Burton G, Pecci A. PLoS One 5 e13279 (2010)
  31. Analysis of the bovine neutrophil transcriptome during glucocorticoid treatment. Weber PS, Madsen-Bouterse SA, Rosa GJ, Sipkovsky S, Ren X, Almeida PE, Kruska R, Halgren RG, Barrick JL, Burton JL. Physiol Genomics 28 97-112 (2006)
  32. Induced-fit docking of mometasone furoate and further evidence for glucocorticoid receptor 17alpha pocket flexibility. Wang H, Aslanian R, Madison VS. J Mol Graph Model 27 512-521 (2008)
  33. Ligand dissociation from estrogen receptor is mediated by receptor dimerization: evidence from molecular dynamics simulations. Sonoda MT, Martínez L, Webb P, Skaf MS, Polikarpov I. Mol Endocrinol 22 1565-1578 (2008)
  34. Study of the impact of the T877A mutation on ligand-induced helix-12 positioning of the androgen receptor resulted in design and synthesis of novel antiandrogens. Zhou J, Liu B, Geng G, Wu JH. Proteins 78 623-637 (2010)
  35. Danshen extract 15,16-dihydrotanshinone I functions as a potential modulator against metabolic syndrome through multi-target pathways. Liu Q, Zhang Y, Lin Z, Shen H, Chen L, Hu L, Jiang H, Shen X. J Steroid Biochem Mol Biol 120 155-163 (2010)
  36. Antiviral effects of mifepristone on human immunodeficiency virus type-1 (HIV-1): targeting Vpr and its cellular partner, the glucocorticoid receptor (GR). Schafer EA, Venkatachari NJ, Ayyavoo V. Antiviral Res 72 224-232 (2006)
  37. Glucocorticoid receptor binding: a biphasic dependence on molecular size as revealed by the bilinear LinBiExp model. Buchwald P. Steroids 73 193-208 (2008)
  38. Single-molecule force spectroscopy reveals folding steps associated with hormone binding and activation of the glucocorticoid receptor. Suren T, Rutz D, Mößmer P, Merkel U, Buchner J, Rief M. Proc Natl Acad Sci U S A 115 11688-11693 (2018)
  39. Modulation of transcription parameters in glucocorticoid receptor-mediated repression. Sun Y, Tao YG, Kagan BL, He Y, Simons SS. Mol Cell Endocrinol 295 59-69 (2008)
  40. Mutations of glucocorticoid receptor differentially affect AF2 domain activity in a steroid-selective manner to alter the potency and efficacy of gene induction and repression. Tao YG, Xu Y, Xu HE, Simons SS. Biochemistry 47 7648-7662 (2008)
  41. Disruption of a key ligand-H-bond network drives dissociative properties in vamorolone for Duchenne muscular dystrophy treatment. Liu X, Wang Y, Gutierrez JS, Damsker JM, Nagaraju K, Hoffman EP, Ortlund EA. Proc Natl Acad Sci U S A 117 24285-24293 (2020)
  42. Effect of hydrocortisone on the production and glycosylation of an Fc-fusion protein in CHO cell cultures. Rouiller Y, Périlleux A, Marsaut M, Stettler M, Vesin MN, Broly H. Biotechnol Prog 28 803-813 (2012)
  43. Identification of dissociated non-steroidal glucocorticoid receptor agonists. Kuzmich D, Kirrane T, Proudfoot J, Bekkali Y, Zindell R, Beck L, Nelson R, Shih CK, Kukulka AJ, Paw Z, Reilly P, Deleon R, Cardozo M, Nabozny G, Thomson D. Bioorg Med Chem Lett 17 5025-5031 (2007)
  44. An F-domain introduced by alternative splicing regulates activity of the zebrafish thyroid hormone receptor alpha. Takayama S, Hostick U, Haendel M, Eisen J, Darimont B. Gen Comp Endocrinol 155 176-189 (2008)
  45. Dynamic allosteric communication pathway directing differential activation of the glucocorticoid receptor. Köhler C, Carlström G, Gunnarsson A, Weininger U, Tångefjord S, Ullah V, Lepistö M, Karlsson U, Papavoine T, Edman K, Akke M. Sci Adv 6 eabb5277 (2020)
  46. Hormone binding and co-regulator binding to the glucocorticoid receptor are allosterically coupled. Pfaff SJ, Fletterick RJ. J Biol Chem 285 15256-15267 (2010)
  47. In silico discovery of androgen receptor antagonists with activity in castration resistant prostate cancer. Shen HC, Shanmugasundaram K, Simon NI, Cai C, Wang H, Chen S, Balk SP, Rigby AC. Mol Endocrinol 26 1836-1846 (2012)
  48. The helix 1-3 loop in the glucocorticoid receptor LBD is a regulatory element for FKBP cochaperones. Cluning C, Ward BK, Rea SL, Arulpragasam A, Fuller PJ, Ratajczak T. Mol Endocrinol 27 1020-1035 (2013)
  49. Corticosteroids modulate the expression of the PKC-anchoring protein RACK-1 and cytokine release in THP-1 cells. Corsini E, Pinto A, Galbiati V, Viviani B, Galli CL, Marinovich M, Racchi M. Pharmacol Res 81 10-16 (2014)
  50. Glucocorticoid Receptor β Acts as a Co-activator of T-Cell Factor 4 and Enhances Glioma Cell Proliferation. Wang Q, Lu PH, Shi ZF, Xu YJ, Xiang J, Wang YX, Deng LX, Xie P, Yin Y, Zhang B, Mu HJ, Qiao WZ, Cui H, Zou J. Mol Neurobiol 52 1106-1118 (2015)
  51. Molecular determinants of the recognition of ulipristal acetate by oxo-steroid receptors. Petit-Topin I, Fay M, Resche-Rigon M, Ulmann A, Gainer E, Rafestin-Oblin ME, Fagart J. J Steroid Biochem Mol Biol 144 Pt B 427-435 (2014)
  52. New naturally occurring missense mutations of the human mineralocorticoid receptor disclose important residues involved in dynamic interactions with deoxyribonucleic acid, intracellular trafficking, and ligand binding. Sartorato P, Cluzeaud F, Fagart J, Viengchareun S, Lombès M, Zennaro MC. Mol Endocrinol 18 2151-2165 (2004)
  53. X-ray structures of progesterone receptor ligand binding domain in its agonist state reveal differing mechanisms for mixed profiles of 11β-substituted steroids. Lusher SJ, Raaijmakers HC, Vu-Pham D, Kazemier B, Bosch R, McGuire R, Azevedo R, Hamersma H, Dechering K, Oubrie A, van Duin M, de Vlieg J. J Biol Chem 287 20333-20343 (2012)
  54. An estrogen receptor chimera senses ligands by nuclear translocation. Martinez ED, Rayasam GV, Dull AB, Walker DA, Hager GL. J Steroid Biochem Mol Biol 97 307-321 (2005)
  55. Structure-transfection activity relationships with glucocorticoid-polyethyl-enimine conjugate nuclear gene delivery systems. Ma K, Hu M, Qi Y, Qiu L, Jin Y, Yu J, Li B. Biomaterials 30 3780-3789 (2009)
  56. The discovery of potent and selective non-steroidal glucocorticoid receptor modulators, suitable for inhalation. Edman K, Ahlgren R, Bengtsson M, Bladh H, Bäckström S, Dahmén J, Henriksson K, Hillertz P, Hulikal V, Jerre A, Kinchin L, Kåse C, Lepistö M, Mile I, Nilsson S, Smailagic A, Taylor J, Tjörnebo A, Wissler L, Hansson T. Bioorg Med Chem Lett 24 2571-2577 (2014)
  57. A ligand-specific kinetic switch regulates glucocorticoid receptor trafficking and function. Trebble PJ, Woolven JM, Saunders KA, Simpson KD, Farrow SN, Matthews LC, Ray DW. J Cell Sci 126 3159-3169 (2013)
  58. A novel mutation of the hGR gene causing Chrousos syndrome. Nicolaides NC, Geer EB, Vlachakis D, Roberts ML, Psarra AM, Moutsatsou P, Sertedaki A, Kossida S, Charmandari E. Eur J Clin Invest 45 782-791 (2015)
  59. First High-Resolution Crystal Structures of the Glucocorticoid Receptor Ligand-Binding Domain-Peroxisome Proliferator-Activated γ Coactivator 1-α Complex with Endogenous and Synthetic Glucocorticoids. Liu X, Wang Y, Ortlund EA. Mol Pharmacol 96 408-417 (2019)
  60. Molecular basis of the interaction specificity between the human glucocorticoid receptor and its endogenous steroid ligand cortisol. von Langen J, Fritzemeier KH, Diekmann S, Hillisch A. Chembiochem 6 1110-1118 (2005)
  61. Revealing a steroid receptor ligand as a unique PPARγ agonist. Lin S, Han Y, Shi Y, Rong H, Zheng S, Jin S, Lin SY, Lin SC, Li Y. Cell Res 22 746-756 (2012)
  62. An examination of how different mutations at arginine 855 of the androgen receptor result in different androgen insensitivity phenotypes. Elhaji YA, Wu JH, Gottlieb B, Beitel LK, Alvarado C, Batist G, Trifiro MA. Mol Endocrinol 18 1876-1886 (2004)
  63. In vitro and in silico assessment of the structure-dependent binding of bisphenol analogues to glucocorticoid receptor. Zhang J, Zhang T, Guan T, Yu H, Li T. Anal Bioanal Chem 409 2239-2246 (2017)
  64. Non-steroidal glucocorticoid receptor antagonists: the race to replace RU-486 for anti-glucocorticoid therapy. Mohler ML, He Y, Wu Z, Hong SS, Miller DD. Expert Opin Ther Pat 17 59-81 (2007)
  65. Regulation of activities of steroid hormone receptors by tibolone and its primary metabolites. Escande A, Servant N, Rabenoelina F, Auzou G, Kloosterboer H, Cavaillès V, Balaguer P, Maudelonde T. J Steroid Biochem Mol Biol 116 8-14 (2009)
  66. Structural basis of the histidine-mediated vitamin D receptor agonistic and antagonistic mechanisms of (23S)-25-dehydro-1alpha-hydroxyvitamin D3-26,23-lactone. Kakuda S, Ishizuka S, Eguchi H, Mizwicki MT, Norman AW, Takimoto-Kamimura M. Acta Crystallogr D Biol Crystallogr 66 918-926 (2010)
  67. A structural explanation of the effects of dissociated glucocorticoids on glucocorticoid receptor transactivation. Dezitter X, Dezitter X, Fagart J, Taront S, Fay M, Masselot B, Hétuin D, Formstecher P, Rafestin-Oblin ME, Idziorek T. Mol Pharmacol 85 226-236 (2014)
  68. Agonist versus antagonist induce distinct thermodynamic modes of co-factor binding to the glucocorticoid receptor. Kroe RR, Baker MA, Brown MP, Farrow NA, Gautschi E, Hopkins JL, LaFrance RR, Kronkaitis A, Freeman D, Thomson D, Nabozny G, Grygon CA, Labadia ME. Biophys Chem 128 156-164 (2007)
  69. Glucocorticoid receptor point mutation V571M facilitates coactivator and ligand binding by structural rearrangement and stabilization. Carlsson P, Koehler KF, Nilsson L. Mol Endocrinol 19 1960-1977 (2005)
  70. Effect of flavonoids on androgen and glucocorticoid receptors based on in vitro reporter gene assay. Nishizaki Y, Ishimoto Y, Hotta Y, Hosoda A, Yoshikawa H, Akamatsu M, Tamura H. Bioorg Med Chem Lett 19 4706-4710 (2009)
  71. Identification of the functional domain of glucocorticoid receptor involved in RU486 antagonism. Lee MS, Choi HS, Kwon SH, Morita K, Her S. J Steroid Biochem Mol Biol 117 67-73 (2009)
  72. Impaired helix 12 dynamics due to proline 892 substitutions in the androgen receptor are associated with complete androgen insensitivity. Elhaji YA, Stoica I, Dennis S, Purisima EO, Lumbroso R, Beitel LK, Trifiro MA. Hum Mol Genet 15 921-931 (2006)
  73. A screening assay for Selective Dimerizing Glucocorticoid Receptor Agonists and Modulators (SEDIGRAM) that are effective against acute inflammation. Souffriau J, Eggermont M, Van Ryckeghem S, Van Looveren K, Van Wyngene L, Van Hamme E, Vuylsteke M, Beyaert R, De Bosscher K, Libert C. Sci Rep 8 12894 (2018)
  74. Synthesis, activity, metabolic stability, and pharmacokinetics of glucocorticoid receptor modulator-statin hybrids. Link JT, Sorensen BK, Lai C, Wang J, Fung S, Deng D, Emery M, Carroll S, Grynfarb M, Goos-Nilsson A, Von Geldern T. Bioorg Med Chem Lett 14 4173-4178 (2004)
  75. Adrenal gland-dependent augmentation of plasminogen activator inhibitor-1 expression in streptozotocin-induced diabetic mice. Oishi K, Ohkura N, Ishida N. J Thromb Haemost 4 1566-1574 (2006)
  76. Combining 3D-QSAR, docking, molecular dynamics and MM/PBSA methods to predict binding modes for nonsteroidal selective modulator to glucocorticoid receptor. Xu Y, Zhang T, Chen M. Bioorg Med Chem Lett 19 393-396 (2009)
  77. Discovery of potent and selective nonsteroidal indazolyl amide glucocorticoid receptor agonists. Sheppeck JE, Gilmore JL, Xiao HY, Dhar TG, Nirschl D, Doweyko AM, Sack JS, Corbett MJ, Malley MF, Gougoutas JZ, Mckay L, Cunningham MD, Habte SF, Dodd JH, Nadler SG, Somerville JE, Barrish JC. Bioorg Med Chem Lett 23 5442-5447 (2013)
  78. Generalized Concentration Addition Model Predicts Glucocorticoid Activity Bioassay Responses to Environmentally Detected Receptor-Ligand Mixtures. Medlock Kakaley E, Cardon MC, Gray LE, Hartig PC, Wilson VS. Toxicol Sci 168 252-263 (2019)
  79. Novel phosphorus-containing 17beta-side chain mifepristone analogues as progesterone receptor antagonists. Jiang W, Allan G, Chen X, Fiordeliso JJ, Linton O, Tannenbaum P, Xu J, Zhu P, Gunnet J, Demarest K, Lundeen S, Sui Z. Steroids 71 949-954 (2006)
  80. Targeting prostate cancer cells with enzalutamide-HDAC inhibitor hybrid drug 2-75. Hu WY, Xu L, Chen B, Ou S, Muzzarelli KM, Hu DP, Li Y, Yang Z, Vander Griend DJ, Prins GS, Qin Z. Prostate 79 1166-1179 (2019)
  81. Alternate glucocorticoid receptor ligand binding structures influence outcomes in an in vivo tissue regeneration model. Sengupta S, Bisson WH, Mathew LK, Kolluri SK, Tanguay RL. Comp Biochem Physiol C Toxicol Pharmacol 156 121-129 (2012)
  82. Discovery of a potent and dissociated non-steroidal glucocorticoid receptor agonist containing an alkyl carbinol pharmacophore. Razavi H, Riether D, Harcken C, Bentzien J, Dinallo RM, Souza D, Nelson RM, Kukulka A, Fadra-Khan TN, Pack EJ, Zuvela-Jelaska L, Pelletier J, Panzenbeck M, Torcellini CA, Proudfoot JR, Nabozny GH, Thomson DS. Bioorg Med Chem Lett 24 1934-1940 (2014)
  83. Function-regulating pharmacophores in a sulfonamide class of glucocorticoid receptor agonists. Kuzmich D, Bentzien J, Betageri R, DiSalvo D, Fadra-Khan T, Harcken C, Kukulka A, Nabozny G, Nelson R, Pack E, Souza D, Thomson D. Bioorg Med Chem Lett 23 6640-6644 (2013)
  84. Permuting input for more effective sampling of 3D conformer space. Carta G, Onnis V, Knox AJ, Fayne D, Lloyd DG. J Comput Aided Mol Des 20 179-190 (2006)
  85. Synthesis and identification of novel oxa-steroids as progesterone receptor antagonists. Kang FA, Allan G, Guan J, Jain N, Linton O, Tannenbaum P, Xu J, Zhu P, Gunnet J, Chen X, Demarest K, Lundeen S, Sui Z. Bioorg Med Chem Lett 17 907-910 (2007)
  86. A multi-parameter imaging assay identifies different stages of ligand-induced androgen receptor activation. van Royen ME, van de Wijngaart DJ, Cunha SM, Trapman J, Houtsmuller AB. Cytometry A 83 806-817 (2013)
  87. Discovery of novel phosphorus-containing steroids as selective glucocorticoid receptor antagonist. Jiang W, Fiordeliso JJ, Allan G, Linton O, Tannenbaum P, Xu J, Zhu P, Gunnet J, Demarest K, Lundeen S, Sui Z. Bioorg Med Chem Lett 17 1471-1474 (2007)
  88. Investigation on critical structural motifs of ligands for triggering glucocorticoid receptor nuclear migration through molecular docking simulations. Liu YL, Jang S, Wang SM, Chen CH, Li FY. J Biomol Struct Dyn 34 1214-1231 (2016)
  89. Nuclear receptor engineering based on novel structure activity relationships revealed by farnesyl pyrophosphate. Goyanka R, Das S, Samuels HH, Cardozo T. Protein Eng Des Sel 23 809-815 (2010)
  90. PCR expression mutagenesis: a high-throughput mutation assay applied to the glucocorticoid receptor ligand-binding domain. Chen J, Blackford JA, Simons SS. Biochem Biophys Res Commun 321 893-899 (2004)
  91. Production of unstable proteins through the formation of stable core complexes. Levy N, Eiler S, Pradeau-Aubreton K, Maillot B, Stricher F, Ruff M. Nat Commun 7 10932 (2016)
  92. Real-time analysis of gene regulation by glucocorticoid hormones. McMaster A, Chambers T, Meng QJ, Grundy S, Loudon AS, Donn R, Ray DW. J Endocrinol 197 205-211 (2008)
  93. Synthesis and activity of novel bile-acid conjugated glucocorticoid receptor antagonists. Richards SJ, von Geldern TW, Jacobson P, Wilcox D, Nguyen P, Ohman L, Osterlund M, Gelius B, Grynfarb M, Goos-Nilsson A, Wang J, Fung S, Kalmanovich M. Bioorg Med Chem Lett 16 6086-6090 (2006)
  94. Synthesis of 6,19-cyclopregnanes. Constrained analogues of steroid hormones. Di Chenna PH, Veleiro AS, Sonego JM, Ceballos NR, Garland MT, Baggio RF, Burton G. Org Biomol Chem 5 2453-2457 (2007)
  95. Synthesis of novel steroidal agonists, partial agonists, and antagonists for the glucocorticoid receptor. Jin Z, Lin H, Srinivasan S, Nwachukwu JC, Bruno N, Griffin PR, Nettles KW, Kamenecka TM. Bioorg Med Chem Lett 27 347-353 (2017)
  96. The multivalency of the glucocorticoid receptor ligand-binding domain explains its manifold physiological activities. Jiménez-Panizo A, Alegre-Martí A, Tettey TT, Fettweis G, Abella M, Antón R, Johnson TA, Kim S, Schiltz RL, Núñez-Barrios I, Font-Díaz J, Caelles C, Valledor AF, Pérez P, Rojas AM, Fernández-Recio J, Presman DM, Hager GL, Fuentes-Prior P, Estébanez-Perpiñá E. Nucleic Acids Res 50 13063-13082 (2022)
  97. Ab initio fragment molecular orbital study of ligand binding to human progesterone receptor ligand-binding domain. Harada T, Yamagishi K, Nakano T, Kitaura K, Tokiwa H. Naunyn Schmiedebergs Arch Pharmacol 377 607-615 (2008)
  98. Design, synthesis, and local anti-inflammatory activity of 17β-carboxamide derivatives of glucocorticoids. Dobričić V, Marković B, Milenković N, Savić V, Jaćević V, Rančić N, Vladimirov S, Cudina O. Arch Pharm (Weinheim) 347 786-797 (2014)
  99. Discovery of new selective glucocorticoid receptor agonist leads. Berger M, Rehwinkel H, Schmees N, Schäcke H, Edman K, Wissler L, Reichel A, Jaroch S. Bioorg Med Chem Lett 27 437-442 (2017)
  100. Identification of dicyclohexyl phthalate as a glucocorticoid receptor antagonist by molecular docking and multiple in vitro methods. Leng Y, Sun Y, Huang W, Lv C, Cui J, Li T, Wang Y. Mol Biol Rep 48 3145-3154 (2021)
  101. Parallel strategies for the preparation and selection of liver-targeted glucocorticoid receptor antagonists. Backes BJ, Hamilton GL, Nguyen P, Wilcox D, Fung S, Wang J, Grynfarb M, Goos-Nilsson A, Jacobson PB, von Geldern TW. Bioorg Med Chem Lett 17 40-44 (2007)
  102. Protein phosphatase 1 alpha enhances glucocorticoid receptor activity by a mechanism involving phosphorylation of serine-211. Patt M, Gysi J, Faresse N, Cidlowski JA, Odermatt A. Mol Cell Endocrinol 518 110873 (2020)
  103. Quaternary glucocorticoid receptor structure highlights allosteric interdomain communication. Postel S, Wissler L, Johansson CA, Gunnarsson A, Gordon E, Collins B, Castaldo M, Köhler C, Öling D, Johansson P, Fröderberg Roth L, Beinsteiner B, Dainty I, Delaney S, Klaholz BP, Billas IML, Edman K. Nat Struct Mol Biol 30 286-295 (2023)
  104. Safer topical treatment for inflammation using 5α-tetrahydrocorticosterone in mouse models. Gastaldello A, Livingstone DE, Abernethie AJ, Tsang N, Walker BR, Hadoke PW, Andrew R. Biochem Pharmacol 129 73-84 (2017)
  105. Selective modulation of glucocorticoid receptor function toward development of novel anti-inflammation: lessons from a phenyl-pyrazolo-steroid cortivazol. Tanaka H, Yoshikawa N, Shimizu N, Morimoto C. Mod Rheumatol 14 347-355 (2004)
  106. Steroidal C-21 heteroaryl thioethers. Part 3: pregn-4-eno-[3,2-c]pyrazole fused A ring modified steroids as selective glucocorticoid receptor modulators (dissociated steroids). Biju P, Wang H, Anthes J, McCormick K, Aslanian R, Berlin M, Bitar R, Lim YH, Lee YJ, Prelusky D, Mcleod R, Jia Y, Fernandez X, Lieber G, Jimenez J, Eckel S, House A, Chapman R, Phillips J. Bioorg Med Chem Lett 22 3291-3295 (2012)
  107. Structural basis for computational screening of non-steroidal androgen receptor ligands. Nyrönen TH, Söderholm AA. Expert Opin Drug Discov 5 5-20 (2010)
  108. A canonical cation-π interaction stabilizes the agonist conformation of estrogen-like nuclear receptors. Queralt-Rosinach N, Mestres J. Eur Biophys J 39 1471-1475 (2010)
  109. Development of nonsteroidal glucocorticoid receptor modulators based on N-benzyl-N-(4-phenoxyphenyl)benzenesulfonamide scaffold. Yoshioka H, Yamada A, Nishiyama Y, Kagechika H, Hashimoto Y, Fujii S. Bioorg Med Chem 25 3461-3470 (2017)
  110. Discovery of liver selective non-steroidal glucocorticoid receptor antagonist as novel antidiabetic agents. Shah K, Patel D, Jadav P, Sheikh M, Sairam KV, Joharapurkar A, Jain MR, Bahekar R. Bioorg Med Chem Lett 22 5857-5862 (2012)
  111. Insight from molecular modeling into different conformation and SAR of natural steroids and unnatural 7-oxa-steroids. Kang FA, Chen X, Jain N, Allan G, Tannenbaum P, Lundeen S, Sui Z. Bioorg Med Chem Lett 18 3687-3690 (2008)
  112. Large-scale, in-cell photocrosslinking at single-residue resolution reveals the molecular basis for glucocorticoid receptor regulation by immunophilins. Baischew A, Engel S, Taubert MC, Geiger TM, Hausch F. Nat Struct Mol Biol 30 1857-1866 (2023)
  113. Synthesis of C-11 modified mifepristone analog libraries. Hamilton GL, Backes BJ. Mol Divers 11 107-111 (2007)
  114. The effect of dexamethasone on lentiviral vector infection is associated with importin α Deng S, Zhou Y, Ouyang D, Xiong J, Zhang L, Tu C, Zhang K, Song Z, Zhang F. Biomed Rep 2 137-141 (2014)
  115. The systematic structure-activity relationship to predict how flavones bind to human androgen receptor for their antagonistic activity. Tamura H, Yoshioka M, Hasegawa M, Hosoda A, Matsugi M, Akamatsu M. Bioorg Med Chem 21 2968-2974 (2013)
  116. Development and validation of an improved inducer-regulator protein complex in the pBRES-regulated expression system. Levitsky K, Szymanski P, Jin F, Meurer-Ogden JA, Harkins RN. Hum Gene Ther 19 1273-1282 (2008)
  117. Protein Condensation in the Nuclear Receptor Family; Implications for Transcriptional Output. Appelman MD, Hollaar EE, Schuijers J, van Mil SWC. Adv Exp Med Biol 1390 243-253 (2022)


Quick links